Search

Heterocycles represent a privileged scaffold due to their ability to interact with biological systems via heteroatoms. It is no coincidence that every year the Food and Drug Administration approves numerous new drugs that contain at least one heterocyclic system as active pharmacophoric part in their structure. Many heterocyclic compounds with therapeutic properties, including anticancer, antimicrobial, anti-inflammatory and so on, come from natural sources such as plants and animals, and medicinal chemists very often use them to study their chemical space and improve their biological activity. In fact, several efficient approaches for the formation of aromatic heterocyclic compounds and their derivatives have been described in the literature in the past, but the development of new green synthetic procedures and methodologies for their high-yield synthesis is increasingly in demand in drug discovery program. This Editorial collects recent research progress in the field of medicinal chemistry focused on the synthesis of new bioactive heterocycles of different types of activities, including anticancer, antibacterial and anti-inflammatory.

In order to develop novel inhibitors of the bacterial deacetylase LpxC bearing a substituent to target the UDP binding site of the enzyme, a series of aldotetronic acid-based hydroxamic acids was accessed in chiral pool syntheses starting from 4,6-O-benzylidene-d-glucose and l-arabinitol. The synthesized hydroxamic acids were tested for LpxC inhibitory activity in vitro, revealing benzyl ether 17a ((2S,3S)-4-(benzyloxy)-N,3-dihydroxy-2-[(4-{[4-(morpholinomethyl)phenyl]ethynyl}benzyl)oxy]butanamide) as the most potent LpxC inhibitor. This compound was additionally tested for antibacterial activity against a panel of clinically relevant Gram-negative bacteria, bacterial uptake, and susceptibility to efflux pumps. Molecular docking studies were performed to rationalize the observed structure-activity relationships.

The discovery of novel synthetic compounds with drug-like properties is an ongoing challenge in medicinal chemistry. Natural products have inspired the synthesis of compounds for pharmaceutical application, most of which are based on N-heterocyclic motifs. Among these, the pyrrole ring is one of the most explored heterocycles in drug discovery programs for several therapeutic areas, confirmed by the high number of pyrrole-based drugs reaching the market. In the present review, we focused on pyrrole and its hetero-fused derivatives with anticancer, antimicrobial, and antiviral activities, reported in the literature between 2015 and 2019, for which a specific target was identified, being responsible for their biological activity. It emerges that the powerful pharmaceutical and pharmacological features provided by the pyrrole nucleus as pharmacophore unit of many drugs are still recognized by medicinal chemists., Graphical abstract Image 1, Highlights • Pyrrole nucleus is one of the most explored heterocycle in drug discovery. • Pyrrole derivatives exhibit antitumor, antimicrobial and antiviral activities. • Targets involved in their biological activities were identified. • SAR to underline their most important features were discussed.